查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985708

治療診斷學市場：全球市場按產品類型、技術、應用領域和最終用戶分類的預測－2026-2032年

Theranostics Market by Product Type, Technology, Application Area, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，治療診斷學市場價值將達到 33.2 億美元，到 2026 年將成長至 37.7 億美元，複合年成長率為 14.16%，到 ​​2032 年將達到 84 億美元。

主要市場統計數據
基準年 2025 33.2億美元
預計年份：2026年 37.7億美元
預測年份 2032 84億美元
複合年成長率 (%) 14.16%

在快速發展的醫療環境中，我們利用診斷和治療的整合來塑造個人化醫療的未來。

治療診斷學代表著醫療保健領域的模式轉移，它有望將診斷準確性和治療效果整合起來，從而重新定義患者的治療結果。診斷與標靶治療的融合正在加速個人化醫療的進程，使臨床醫生能夠根據分子譜、疾病進展標記和個體反應模式來最佳化治療方法。隨著影像學、生物標記和新型藥物傳遞機制的融合發展，臨床決策的基礎正在被重構，其核心是高度特異性和數據驅動的路徑。

技術和科學突破重新定義了臨床環境中治療診斷學解決方案的開發和整合。

在分子影像學突破、先進生物標記發現以及奈米技術平台蓬勃發展的推動下，治療診斷學領域正經歷著翻天覆地的變革。放射性藥物偶聯和標靶藥物遞送系統等技術創新，為以前所未有的精準度可視化和治療病灶提供了前所未有的機會。隨著次世代定序和機器學習演算法更深入地融入臨床工作流程，診斷測試的預測能力正在改變治療候選藥物的選擇和給藥方式。

對美國關稅政策對全球供應鏈和診療治療診斷學趨勢的影響進行全面評估。

美國在2025年實施的關稅政策給全球治療診斷學供應鏈帶來了巨大壓力，尤其是在放射性藥物前驅物和專用診斷劑的採購方面。隨著關鍵原料進口成本的上升，製造商被迫重新評估其籌資策略，越來越依賴區域合作夥伴並尋求垂直整合，以保護自身業務免受關稅波動的影響。同時，研究機構也在評估替代試劑和同位素，以期在不影響分析性能的前提下，提供更具成本效益的解決方案。

對治療診斷學產品（產品、技術、應用、最終用戶）的每個層面進行詳細的細分分析，以識別機會和挑戰。

基於產品的檢驗細分錶明，診斷試劑和治療試劑之間的二分法凸顯了不同的創新路徑。診斷試劑越來越注重能夠檢測微量殘存疾病的高靈敏度分子成像探針，而治療試劑則優先考慮能夠同時監測治療和藥物遞送的多功能結構。這種產品類型之間的相互作用形成了一個回饋迴路：診斷技術的進步會影響治療標靶參數的調整，反之亦然。

揭示美洲、歐洲、中東和非洲以及亞太市場治療診斷學解決方案擴張的區域特定促進因素和部署模式。

治療診斷學的區域發展趨勢體現在應用率和創新生態系的差異。在美洲，分子影像和放射化學的基礎設施已經成熟，健全的法規環境也促進了伴隨診斷的早期應用。先進的支付模式和高度集中的學術研究中心正在推動整合診斷和治療模式的快速普及，尤其是在腫瘤學領域。

本文重點介紹了透過顛覆性研發和市場定位，推動治療診斷學系統內創新和策略合作的先鋒組織。

治療診斷學領域的主要企業因其整合跨學科研究能力和策略合作夥伴關係的能力而脫穎而出。一些開創性的生物技術和製藥公司已建立內部放射化學和分子影像部門，以加速早期研發；與此同時，診斷領域的創新者正在建立合作開發夥伴關係，將伴隨診斷整合到治療產品線中。由此產生的專業知識交流正在催生超越醫療設備、診斷和製藥領域傳統界限的混合經營模式。

為產業領導者建立切實可行的策略路徑，以利用治療診斷學市場的技術進步和監管趨勢。

產業領導者應採用協作式開發框架，整合診斷與治療研發團隊，打造無縫銜接的創新路徑。從產品設計早期階段就引入跨職能協作，可最大限度地減少研發重複，縮短核准時間，並協調監管溝通策略。透過採用一體化的計劃管治結構，企業可以同步推進檢測方法、影像通訊協定和候選治療藥物的研發進程。

闡明用於收集、檢驗和整合治療診斷學市場分析中多維度資料的系統研究框架。

本分析的研究架構採用多層方法，以確保其穩健性和有效性。二手資訊來源包括同行評審的科學論文、監管文件和行業白皮書，這些資料提供了關於新興技術、政策趨勢和臨床試驗結果的基礎性見解。這項桌上研究為識別治療診斷學系統各個方面的關鍵趨勢以及理解其競爭動態奠定了基礎。

透過整合核心見解，這項工作重點闡述了診斷、治療和新興技術之間的協同作用將如何推動下一代個人化醫療的發展。

診斷準確性和治療特異性的融合正在為個人化醫療開闢新道路，而治療診斷學）正處於這一變革的前沿。核心研究表明，從先進的分子成像到基於奈米技術的遞送系統，各項技術創新正在重新定義疾病檢測和治療的範式。監管流程向整合核准流程的轉變以及支付方對基於結果的報銷模式的關注，都為這些進展提供了支持。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章治療診斷學市場：依產品類型分類

  • 診斷藥物
  • 治療藥物

第9章治療診斷學市場：依技術分類

  • 基於生物標記的治療診斷學
  • 伴隨診斷（CDx）
  • 基於基因療法的治療診斷學
  • 分子影像
  • 基於奈米科技的治療診斷學
  • 基於放射性藥物的治療診斷學
  • 標靶藥物遞送

第10章治療診斷學市場：依應用領域分類

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
  • 發炎性疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 神經內分泌腫瘤
    • 攝護腺癌
    • 甲狀腺癌

第11章治療診斷學市場：依最終用戶分類

  • 診斷影像中心
  • 醫院及癌症治療中心
  • 研究和學術機構
  • 專科診所

第12章治療診斷學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章治療診斷學市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章治療診斷學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國治療診斷學市場

第16章：中國治療診斷學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMerieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
Product Code: MRR-61081604A0A5

The Theranostics Market was valued at USD 3.32 billion in 2025 and is projected to grow to USD 3.77 billion in 2026, with a CAGR of 14.16%, reaching USD 8.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.32 billion
Estimated Year [2026] USD 3.77 billion
Forecast Year [2032] USD 8.40 billion
CAGR (%) 14.16%

Harnessing the Convergence of Diagnostics and Therapeutics to Shape the Future of Personalized Healthcare in a Rapidly Evolving Landscape

Theranostics represents a paradigm shift in healthcare, uniting diagnostic precision and therapeutic efficacy into integrated solutions that promise to redefine patient outcomes. This fusion of diagnostics and targeted treatment is accelerating the movement toward personalized medicine, enabling clinicians to tailor interventions based on molecular profiles, disease progression markers, and individual response patterns. As the confluence of imaging, biomarkers, and novel drug delivery mechanisms gains momentum, the very fabric of clinical decision-making is being rewoven to center on highly specific, data-driven pathways.

In this rapidly evolving landscape, stakeholders across research, regulatory, and commercial domains are rallying around the potential of theranostic platforms to streamline drug development timelines, reduce adverse events, and enhance therapeutic indices. The integration of companion diagnostics with cutting-edge therapeutic agents is laying the groundwork for agile clinical trials and adaptive treatment protocols. Consequently, a growing ecosystem of interdisciplinary collaboration is emerging, fueled by converging expertise in molecular biology, radiology, nanotechnology, and bioinformatics.

Looking ahead, the maturation of theranostic frameworks will hinge on robust partnerships between innovators and healthcare providers, supported by regulatory clarity and reimbursement structures that acknowledge value-based outcomes. As this introduction sets the stage, subsequent sections will delve into transformative shifts, policy impacts, market segmentation, regional dynamics, and strategic imperatives that define the trajectory of theranostic advancements.

Unveiling the Technological and Scientific Breakthroughs Redefining How Theranostic Solutions Are Developed and Integrated Across Clinical Settings

The theranostic landscape is undergoing profound transformation driven by breakthroughs in molecular imaging, advanced biomarker discovery, and the proliferation of nanotechnology-based platforms. Technological innovations such as radiopharmaceutical conjugation and targeted drug delivery vehicles are unlocking unprecedented opportunities to visualize and treat disease loci with pinpoint accuracy. As next-generation sequencing and machine learning algorithms become more deeply entwined with clinical workflows, the predictive power of diagnostic assays is reshaping how therapeutic candidates are selected and administered.

Moreover, regulatory frameworks are progressively adapting to accommodate the dualistic nature of theranostic products. Regulatory agencies are engaging in more frequent stakeholder dialogues to streamline approval pathways, particularly for biomarker-based companion diagnostics. This shift is fostering a more integrated evaluation process that views diagnostics and therapeutics as a unified entity, thereby reducing time-to-market and fostering innovation incentives. At the same time, payers are exploring outcomes-based reimbursement models that reward precision medicine approaches, underscoring the economic rationale for integrated testing and treatment modalities.

From a commercialization standpoint, strategic alliances and in-licensing agreements are proliferating, as pharmaceutical and diagnostic companies seek to co-develop or cross-license complementary assets. These partnerships reflect an industry-wide recognition that no single entity can master the spectrum of capabilities-from advanced imaging instrumentation to molecular assay design and therapeutic formulation-required to deliver holistic theranostic solutions. Ultimately, these transformative shifts are not only redefining product roadmaps but also catalyzing a culture of translational science that bridges laboratory discoveries with bedside impact.

Assessing the Comprehensive Effects of United States Tariff Policies on Global Supply Chains and Research Dynamics in Theranostic Development

The introduction of United States tariffs in 2025 has exerted notable pressure on global theranostic supply chains, particularly in the procurement of radiopharmaceutical precursors and specialized diagnostic reagents. As import costs for key raw materials rise, manufacturers are being compelled to reassess sourcing strategies, often turning to regional partners or pursuing vertical integration to insulate operations from tariff-induced volatility. In parallel, research institutions are evaluating alternative reagents and isotopes that may offer more favorable cost structures without compromising analytical performance.

Amid these dynamics, some stakeholders are intensifying efforts to localize production of essential components, spurred by government incentives aimed at promoting domestic manufacturing capabilities. This localization trend is fostering new collaborations between biotech firms, contract manufacturing organizations, and academic centers to scale up radiochemistry facilities. Although such initiatives entail significant capital investment, the resulting supply chain resilience and reduced exposure to external tariff fluctuations are driving long-term strategic value.

Furthermore, the tariff landscape has precipitated a reevaluation of cross-border clinical trial networks. Sponsors are increasingly factoring in logistical complexities and potential delays when selecting clinical sites, particularly if the movement of diagnostic kits and radiopharmaceuticals is subject to heightened customs scrutiny. These considerations are leading to more geographically diversified trial designs, with a parallel emphasis on harmonizing regulatory requirements and ensuring standardized quality control across multiple jurisdictions. As a result, the cumulative impact of tariffs is reshaping both operational models and strategic frameworks within the theranostic ecosystem.

Mining In-Depth Segmentation Perspectives to Illuminate Opportunities and Challenges Across Theranostic Product, Technology, Application and End-User Tiers

In examining product-based segmentation, the dichotomy between diagnostic agents and therapeutic agents underscores divergent innovation trajectories. Diagnostic agents are increasingly focusing on high-sensitivity molecular imaging probes that can detect minimal residual disease, whereas therapeutic agents are prioritizing multifunctional constructs capable of simultaneous treatment monitoring and drug delivery. This interplay between product types is fostering a feedback loop in which diagnostic refinements inform therapeutic targeting parameters, and vice versa.

The technological segmentation reveals an expansive array of platforms shaping the field. Biomarker-based theranostics are benefiting from next-generation sequencing insights, companion diagnostics are gaining regulatory traction alongside targeted oncology therapies, and gene therapy-based approaches are integrating diagnostic triggers for conditional expression. Molecular imaging enhancements are improving spatial resolution, nanotechnology-based carriers are optimizing pharmacokinetics, radiopharmaceutical-based constructs are evolving with novel isotopes, and targeted drug delivery systems are achieving higher payload specificity. Each of these technological categories interacts synergistically, creating a mosaic of innovation where advances in one domain catalyze progress in another.

Application-area segmentation highlights that oncology remains the nucleus of theranostic deployment, with breast cancer, lung cancer, neuroendocrine tumors, prostate cancer, and thyroid cancer leading research efforts. Concurrently, autoimmune, cardiovascular, infectious, inflammatory, metabolic, and neurological disorders are receiving increasing therapeutic attention as diagnostic modalities become more versatile. Within end-user segmentation, diagnostic imaging centers, hospitals and cancer care centers, research and academic institutes, and specialty clinics are tailoring their service offerings to accommodate integrated test-and-treat protocols. These segments are forging distinct value propositions while leveraging shared technological innovations to address expanding clinical horizons.

Deciphering Unique Regional Drivers and Adoption Patterns Shaping Expansion of Theranostic Solutions Across Americas, EMEA and Asia-Pacific Markets

Regional dynamics in theranostics are characterized by differentiated adoption velocities and innovation ecosystems. In the Americas, established infrastructure for molecular imaging and radiochemistry is complemented by a robust regulatory environment that encourages early adoption of companion diagnostics. Progressive payer models and a high concentration of academic research centers are driving rapid incorporation of integrated test-and-treat paradigms, particularly in oncology.

Meanwhile, Europe, the Middle East & Africa present a heterogeneous landscape marked by pockets of excellence in precision oncology hubs, alongside regions where limited reimbursement frameworks and infrastructure gaps impede widespread deployment. Regulatory harmonization initiatives within the European Union are streamlining cross-border collaboration, while Middle Eastern and North African governments are increasingly investing in specialized facilities to attract clinical research initiatives. Africa's landscape is more nascent but holds promise as diagnostic capabilities expand through public-private partnerships.

In Asia-Pacific, a dynamic convergence of government-led healthcare modernization, a growing middle-income population, and entrepreneurial biotech ecosystems is fueling demand for theranostic solutions. Countries with established nuclear medicine programs are leading in radiopharmaceutical applications, while emerging markets are prioritizing more accessible biomarker-based diagnostics. Collaborative research networks across academic hospitals and industry consortia are laying the groundwork for broad-based adoption, positioning the region as a critical frontier for future growth.

Spotlighting Pioneering Organizations Driving Innovation and Strategic Collaborations in the Theranostics Ecosystem with Disruptive R&D and Market Positioning

Leading organizations in the theranostic domain are distinguished by their ability to integrate multidisciplinary research capabilities with strategic alliances. Several pioneering biotech and pharmaceutical companies are establishing in-house radiochemistry and molecular imaging divisions to accelerate early development, while diagnostic innovators are forging co-development partnerships to embed companion tests within therapeutic pipelines. The resulting cross-pollination of expertise is giving rise to hybrid business models that transcend traditional boundaries between device, diagnostic, and pharmaceutical segments.

Strategic collaborations between academic research institutes and commercial entities are further enriching the innovation landscape. By leveraging academic centers' deep knowledge of disease biology and pharmaceutical companies' development resources, these partnerships are expediting translational research and enabling seamless transition from bench to bedside. In parallel, contract research organizations and contract manufacturing specialists are scaling customized manufacturing processes for complex agents, ensuring regulatory compliance and quality control across global markets.

Investment activity is also influencing company positioning, as venture capital and corporate investors target next-generation platforms such as gene therapy-based theranostics and nanocarrier systems. These inflows are enabling smaller players to challenge incumbents by rapidly advancing niche applications or high-precision diagnostic tools. Collectively, these company-level initiatives underscore a competitive landscape where agility, technical depth, and collaborative acumen determine leadership in the theranostic ecosystem.

Crafting Pragmatic Strategic Pathways for Industry Leaders to Capitalize on Technological Advances and Regulatory Trends in the Theranostics Market

Industry leaders should embrace co-development frameworks that unite diagnostic and therapeutic R&D teams to foster seamless innovation pathways. Embedding cross-functional collaboration at the outset of product design will minimize development redundancies, shorten approval timelines, and align regulatory engagement strategies. By adopting integrated project governance structures, organizations can ensure synchronized advancement of assays, imaging protocols, and therapeutic candidates.

Furthermore, establishing regional manufacturing and distribution hubs can mitigate exposure to supply chain disruptions, including tariff-induced cost pressures. Investing in decentralized radiopharmaceutical production facilities and diversifying sourcing of critical reagents will enhance operational resilience. Concurrently, engaging proactively with reimbursement authorities to demonstrate clinical and economic value through real-world evidence generation will secure favorable coverage policies, unlocking broader patient access.

Finally, leveraging digital platforms and artificial intelligence tools to analyze longitudinal patient data will enable dynamic refinement of theranostic algorithms and personalized treatment pathways. Executives should prioritize partnerships with data analytics providers and invest in interoperable IT infrastructure to drive continuous performance optimization. These actionable steps will empower companies to navigate regulatory complexities, capitalize on technology advances, and cement leadership in the evolving theranostic arena.

Unraveling the Systematic Research Framework Employed to Gather, Validate, and Synthesize Multidimensional Data in Theranostic Market Analysis

The research framework underpinning this analysis employed a multi-tiered approach to ensure robustness and validity. Secondary data sources included peer-reviewed scientific publications, regulatory filings, and industry white papers, which provided foundational insights into emerging technologies, policy developments, and clinical trial outcomes. This desk research laid the groundwork for identifying key trends and mapping competitive dynamics across multiple dimensions of the theranostic ecosystem.

Primary research comprised in-depth interviews with subject-matter experts spanning academic researchers, clinical practitioners, diagnostic developers, and pharmaceutical executives. These interviews yielded qualitative perspectives on development challenges, regulatory nuances, and market adoption barriers. To enhance triangulation, primary responses were cross-verified with publicly available case studies and clinical trial registries, ensuring that interpretations aligned with empirical evidence and real-world outcomes.

Quantitative data analysis involved synthesizing operating metrics, scientific publication trends, and patent filings to gauge innovation trajectories. Data modeling techniques were applied to uncover correlations between technological maturation, regulatory shifts, and adoption rates. The combination of qualitative insights and quantitative validation facilitated a comprehensive view of the theranostic domain, enabling actionable conclusions and strategic recommendations that reflect both current realities and future potential.

Consolidating Core Insights to Highlight How Synergies Between Diagnostics Therapeutics and Emerging Technologies Will Drive the Next Era of Personalized Medicine

The convergence of diagnostic precision and therapeutic specificity is charting a new course for personalized healthcare, with theranostics at the forefront of this transformation. Core insights reveal that technological innovations-from molecular imaging enhancements to nanotechnology-based delivery systems-are redefining disease detection and treatment paradigms. These advancements are supported by regulatory momentum toward integrated approval pathways and payer interest in outcomes-driven reimbursement models.

Segmentation analysis emphasizes the interplay between product types, technology platforms, application areas, and end-user settings, highlighting where value creation opportunities intersect. Regional perspectives underscore the importance of localized infrastructure, regulatory harmonization, and targeted research initiatives in unlocking market potential. Company-level insights further demonstrate that collaborative R&D, agile manufacturing strategies, and strategic investments are critical factors shaping competitive advantage.

In sum, the next era of theranostics will be driven by synergies between diagnostics, therapeutics, and data analytics, fostering a healthcare ecosystem that delivers tailored interventions with improved efficacy and reduced toxicity. Stakeholders who strategically align across scientific, regulatory, and commercial dimensions will be best positioned to translate these synergies into sustainable growth and enhanced patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Theranostics Market, by Product Type

  • 8.1. Diagnostic Agents
  • 8.2. Therapeutic Agents

9. Theranostics Market, by Technology

  • 9.1. Biomarker-Based Theranostics
  • 9.2. Companion Diagnostics (CDx)
  • 9.3. Gene Therapy-Based Theranostics
  • 9.4. Molecular Imaging
  • 9.5. Nanotechnology-Based Theranostics
  • 9.6. Radiopharmaceutical-Based Theranostics
  • 9.7. Targeted Drug Delivery

10. Theranostics Market, by Application Area

  • 10.1. Autoimmune Disorders
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Diseases
  • 10.4. Inflammatory Diseases
  • 10.5. Metabolic Disorders
  • 10.6. Neurological Disorders
  • 10.7. Oncology
    • 10.7.1. Breast Cancer
    • 10.7.2. Lung Cancer
    • 10.7.3. Neuroendocrine Tumors
    • 10.7.4. Prostate Cancer
    • 10.7.5. Thyroid Cancer

11. Theranostics Market, by End-User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals & Cancer Care Centers
  • 11.3. Research & Academic Institutes
  • 11.4. Specialty Clinics

12. Theranostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Theranostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Theranostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Theranostics Market

16. China Theranostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Actinium Pharmaceuticals, Inc.
  • 17.6. Ariceum Therapeutics GmbH
  • 17.7. Astellas Pharma Inc.
  • 17.8. BAMF Health
  • 17.9. Bayer AG
  • 17.10. bioMerieux SA
  • 17.11. Biosynth Ltd.
  • 17.12. Cardinal Health, Inc.
  • 17.13. Cerebral Therapeutics, Inc.
  • 17.14. Clarity Pharmaceuticals
  • 17.15. Curasight A/S
  • 17.16. Curium Inc.
  • 17.17. Evergreen Theragnostics, Inc.
  • 17.18. GE HealthCare Technologies, Inc.
  • 17.19. Hermes Medical Solutions AB
  • 17.20. Icon Group
  • 17.21. Indi Molecular, Inc.
  • 17.22. Integrated Clinical Oncology Network Pty Ltd.
  • 17.23. Radiopharm Theranostics Limited
  • 17.24. Ratio Therapeutics
  • 17.25. Siemens Healthineers AG
  • 17.26. SOFIE Co.
  • 17.27. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS THERANOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL THERANOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GCC THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 142. GCC THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. G7 THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. G7 THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 160. G7 THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. NATO THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 166. NATO THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)